{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Harvard Bioscience, Inc.
Is Harvard Bioscience, Inc. technically bullish or bearish?
As of June 3, 2025, Harvard Bioscience, Inc. shows a mildly bearish trend, with mixed signals from key indicators like MACD, moving averages, and Bollinger Bands suggesting weak bearish sentiment in the short term.
Who are in the management team of Harvard Bioscience, Inc.?
As of March 2022, the management team of Harvard Bioscience, Inc. includes Mr. James Green as Chairman, President, and CEO, with Mr. Bertrand Loy serving as Lead Independent Director and several independent directors including Ms. Katherine Eade and Mr. Alan Edrick.
What does Harvard Bioscience, Inc. do?
Harvard Bioscience, Inc. develops and markets scientific instruments and lab consumables for research and testing in the Pharmaceuticals & Biotechnology industry. As of March 2025, it reported net sales of $22 million and a net profit loss of $50 million, with a market cap of $21.69 million.
How big is Harvard Bioscience, Inc.?
As of Jun 18, Harvard Bioscience, Inc. has a market capitalization of 21.69 million and reported net sales of 91.40 million, with a net profit loss of 58.05 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
